Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K. Paik, Xiuning Le, Alexis B. Cortot et al.|New England Journal of Medicine|2020Cited by 879
Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>MET</i>ex14 skipping.Xiuning Le, Paul K. Paik, Enriqueta Felip et al.|Journal of Clinical Oncology|2020Cited by 4